This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weng, J.-R. Articles by Chen, C.-S. Search for Related Content PubMed PubMed Citation Articles by Weng, J.-R. Articles by Chen, C.-S.

A Potent Indole-3-Carbinol–Derived Antitumor Agent with Pleiotropic Effects on Multiple Signaling Pathways in Prostate Cancer Cells

¹ Department of Biological Science and Technology, China Medical University; ² China Medical University Hospital, Taichung, Taiwan; and ³ Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, Ohio

Requests for reprints: Ching-Shih Chen, Division of Medicinal Chemistry, College of Pharmacy, Parks Halls, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210. Phone: 614-688-4008; Fax: 614-688-8556; E-mail: chen.844{at}osu.edu.

Indole-3-carbinol has emerged as a promising chemopreventive agent due to its in vivo efficacy in various animal models. However, indole-3-carbinol exhibits weak antiproliferative potency and is unstable in acidic milieu. Thus, this study was aimed at exploiting indole-3-carbinol to develop potent antitumor agents with improved chemical stability. This effort culminated in OSU-A9 {[1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol}, which is resistant to acid-catalyzed condensation, and exhibits 100-fold higher apoptosis-inducing activity than the parent compound. Relative to indole-3-carbinol, OSU-A9 displays a striking qualitative similarity in its effects on the phosphorylation or expression of multiple signaling targets, including Akt, mitogen-activated protein kinases, Bcl-2 family members, survivin, nuclear factor-B, cyclin D1, p21, and p27. The ability of OSU-A9 to concurrently modulate this broad range of signaling targets underscores its in vitro and in vivo efficacy in prostate cancer cells. Nevertheless, despite this complex mode of mechanism, normal prostate epithelial cells were less susceptible to the antiproliferative effect of OSU-A9 than PC-3 and LNCaP prostate cancer cells. Treatment of athymic nude mice bearing established s.c. PC-3 xenograft tumors with OSU-A9 at 10 and 25 mg/kg i.p. for 42 days resulted in a 65% and 85%, respectively, suppression of tumor growth. Western blot analysis of representative biomarkers in tumor lysates revealed significant reductions in the intratumoral levels of phosphorylated (p-) Akt, Bcl-xL, and RelA, accompanied by robust increases in p-p38 levels. In conclusion, the ability of OSU-A9 to target multiple aspects of cancer cell survival with high potency suggests its clinical value in prostate cancer therapy. [Cancer Res 2007;67(16):7815–24]

This article has been cited by other articles:

				H. A. Omar, A. M. Sargeant, J.-R. Weng, D. Wang, S. K. Kulp, T. Patel, and C.-S. Chen Targeting of the Akt-Nuclear Factor-{kappa}B Signaling Network by [1-(4-Chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a Novel Indole-3-Carbinol Derivative, in a Mouse Model of Hepatocellular Carcinoma Mol. Pharmacol., November 1, 2009; 76(5): 957 - 968. [Abstract] [Full Text] [PDF]

				J.-R. Weng, C.-H. Tsai, H. A. Omar, A. M. Sargeant, D. Wang, S. K. Kulp, C. L. Shapiro, and C.-S. Chen OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-{kappa}B pathway and stress response signaling Carcinogenesis, October 1, 2009; 30(10): 1702 - 1709. [Abstract] [Full Text] [PDF]

				H. Yin, A. Chu, W. Li, B. Wang, F. Shelton, F. Otero, D. G. Nguyen, J. S. Caldwell, and Y. A. Chen Lipid G Protein-coupled Receptor Ligand Identification Using {beta}-Arrestin PathHunterTM Assay J. Biol. Chem., May 1, 2009; 284(18): 12328 - 12338. [Abstract] [Full Text] [PDF]